Nicotinamide and Other Benzamide Analogs as Agents for Overcoming Hypoxic Cell Radiation Resistance in Tumours

References

• Hall E J. Radiobiology for the radiologist, 4th ed. Harper and Row, Philadelphia 1994
   Google Scholar
• Guichard M, Courdi A, Malaise E P. Experimental data on the radiobiology of solid tumours. Eur J Radiother 1980; 1: 171–91
   Google Scholar
• Moulder J E, Rockwell S. Hypoxic fractions of solid tumours. Int J Radiat Oncol Biol Phys 1984; 10: 695–712
   PubMedGoogle Scholar
• Dische S. The clinical consequences of the oxygen effect. The biological basis of radiotherapy, 2nd ed, G G Steel, G E Adams, A Horwich. Elsevier Science, Amsterdam 1989; 135–44
   Google Scholar
• Overgaard J. Sensitization of hypoxic tumour cells—clinical experience. Int J Radiat Biol 1989; 56: 801–11
   PubMed Web of Science ®Google Scholar
• Overgaard J, Horsman M R. Overcoming hypoxic cell radioresistance. Basic clinical radiobiology for radiation oncologists, G G Steel. Edward Arnold, London 1993; 163–72
   Google Scholar
• Brown D M, Yu N Y, Lee W W, Brown J M. Non-nitro radiosensitizers: In vivo and in vitro sensitization with amine-N-oxides. Abstracts of the Thirtieth Annual Meeting of the Radiation Research Society, Salt Lake City, UT, April 18–22, 1982, Gc-21
   Google Scholar
• Horsman M R, Brown D M, Lemmon M J, Brown J M, Lee W W. Preferential tumour radiosensitization by analogs of nicotinamide and benzamide. Int J Radiat Oncol Biol Phys 1986; 12: 1307–10
   PubMed Web of Science ®Google Scholar
• Horsman M R, Brown J M, Hirst V K, et al. Mechanism of action of the selective tumour radiosensitizer nicotinamide. Int J Radiat Oncol Biol Phys 1988; 15: 685–90
   PubMed Web of Science ®Google Scholar
• Horsman M R, Chaplin D J, Brown J M. Tumour radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res 1989; 118: 139–50
   PubMed Web of Science ®Google Scholar
• Schwarz G. Ueber Desensibilisierung gegen Röntgen- und Radiumstrahlen. Münch Med Wschr 1909; 56: 1217–8
   Google Scholar
• Thomlinson R H, Gray L H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539–49
   PubMed Web of Science ®Google Scholar
• Horsman M R. Hypoxia in tumours: its relevance, identification and modification. Current topics in clinical radiobiology of tumours, H P Beck-Bornholdt. Springer-Verlag, Berlin 1993; 99–112
   Google Scholar
• Chapman J D, Urtasun R C, Franko A J, Raleigh J A, Meeker B E, McKinnon S A. The measurement of oxygenation status of individual tumors. Prediction of response in radiation therapy. Part I. The physical and biological basis, B R Paliwal, J F Fowler, D E Herbert, T J Kinsella, C G Orton. An American Institute of Physics, Inc., New York 1989; 49–60
   Google Scholar
• Stone H B, Brown J M, Phillips T L, Sutherland R M. Oxygen in human tumors: Correlations between methods of measurement and response to therapy. Radiat Res 1993; 136: 422–34
   PubMed Web of Science ®Google Scholar
• Tannock I F. The relationship between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer 1968; 22: 258–73
   PubMed Web of Science ®Google Scholar
• Horsman M R, Overgaard J. Overcoming tumour radiation resistance resulting from acute hypoxia. Eur J Cancer 1992; 28A: 717–8
   PubMed Web of Science ®Google Scholar
• Folkman J. The vascularization of tumours. Sci Am 1976; 234: 58–73
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4–6
   PubMed Web of Science ®Google Scholar
• Warren B A. The vascular morphology of tumours. Tumour blood circulation: angiogenesis, vascular morphology and blood flow of experimental and human tumours, H-I Peterson. CRC Press, Boca Raton, Fl. 1979; 1–47
   Google Scholar
• Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours: a review. Cancer Res 1989; 49: 6449–65
   PubMed Web of Science ®Google Scholar
• Vaupel P. Oxygen supply to malignant tumours. Tumour blood circulation: angiogenesis, vascular morphology and blood flow of experimental and human tumours, H-I Peterson. CRC Press, Boca Raton, Fl. 1979; 143–68
   Google Scholar
• Wike-Hooley J L, Haveman Reinhold J. HS. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 1984; 2: 343–66
   PubMed Web of Science ®Google Scholar
• Brown J M. Evidence for acutely hypoxic cells in mouse tumours and a possible mechanism of reoxygenation. Br J Radiol 1979; 52: 650–6
   PubMed Web of Science ®Google Scholar
• Sutherland R M, Franko A J. On the nature of the radiobiologically hypoxic fraction in tumors. Int J Radiat Oncol Biol Phys 1980; 6: 117–20
   PubMed Web of Science ®Google Scholar
• Chaplin D J, Durand R E, Olive P L. Acute hypoxia in tumors: implication for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 1986; 12: 1279–82
   PubMed Web of Science ®Google Scholar
• Chaplin D J, Olive P L, Durand R E. Intermittenl blood flow in a murine tumour: radiobiological effects. Cancer Res 1987; 47: 597–601
   PubMed Web of Science ®Google Scholar
• Chaplin D J, Trotter M J. Chemical modifiers of tumour blood flow. Tumour blood supply and metabolic microenvironment, P Vaupel, R K Jain. Gustav Fischer, Stuttgart 1991; 65–85
   Google Scholar
• Horsman M R, Chaplin D J, Overgaard J. Combination of nicotiamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumour cells. Cancer Res 1990; 50: 7430–6
   PubMed Web of Science ®Google Scholar
• Jirtle R L. Chemical modification of tumour blood flow. Int J Hyperthermia 1988; 4: 355–71
   PubMed Web of Science ®Google Scholar
• Jain R K. Determinants of tumour blood flow: a review. Cancer Res 1988; 48: 2641–58
   PubMed Web of Science ®Google Scholar
• Sevick E M, Jain R K. Geometric resistance to blood flow in solid tumours perfused ex vivo: effects of tumour size and perfusion pressure. Cancer Res 1989; 49: 3506–12
   PubMed Web of Science ®Google Scholar
• Intaglietta M, Myers R R, Gross J F, Reinhold H S. Dynamics of microvascular flow in implanted mouse mammary tumours. Bibl Anat 1977; 15: 237–76
   Google Scholar
• Reinhold H S, Blackiewicz B, Block A. Oxygenation and reoxygenation in ‘sandwich’ tumours. Bibl Anat 1977; 15: 270–2
   Google Scholar
• Suzuki M, Hori K, Abe I, Saito S, Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 1981; 67: 663–9
   PubMed Web of Science ®Google Scholar
• Burton M A, Gray B N, Self G W, Heggie J C, Townsend P S. Manipulation of experimental rat and rabbit liver tumour blood flow with angiotensin II. Cancer Res 1985; 45: 5390–3
   PubMed Web of Science ®Google Scholar
• Hafström L, Nobin A, Persson B, Sundqvist K. Effects of catecholamines on cardiovascular response and blood flow distribution to normal tissue and liver tumours in rats. Cancer Res 1980; 40: 481–5
   PubMed Web of Science ®Google Scholar
• Kaelin W G, Shrivastava S, Shand D G, Jirtle R L. Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats. Cancer Res 1982; 42: 3944–9
   PubMed Web of Science ®Google Scholar
• Wood P J, Hirst D G. Calcium antagonists as radiation modifiers: site specificity in relation to tumour response. Int J Radiat Oncol Biol Phys 1989; 16: 1141–4
   PubMed Web of Science ®Google Scholar
• Zanelli G D, Lucas P B, Fowler J F. The effect of anaesthetics on blood perfusion I. Br J Cancer 1975; 32: 380–90
   PubMed Web of Science ®Google Scholar
• Menke H, Vaupel P. Effect of injectable or inhalational anaesthetics and of neuroleptic, neuroleptanalgesic, and sedative agents on tumour blood flow. Radiat Res 1988; 114: 64–76
   PubMed Web of Science ®Google Scholar
• Song C W. Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 1984; 44((Suppl))4721s–30s
   Google Scholar
• Suit H D, Marshall N, Woerner D. Oxygen, oxygen plus carbon dioxide, and radiation therapy of a mouse mammary carcinoma. Cancer 1972; 30: 1154–8
   PubMed Web of Science ®Google Scholar
• Rojas A. Radiosensitization with normobaric oxygen and carbogen. Radiother Oncol 1991; 20((Suppl))65–70
   PubMedGoogle Scholar
• Rockwell S. Use of a perfluorochemical emulsion to improve oxygenation in a solid tumour. Int J Radiat Oncol Biol Phys 1985; 11: 97–103
   PubMed Web of Science ®Google Scholar
• Rockwell S, Kelley M, Irvin C G, et al. Modulation of tumour oxygenation and radiosensitivity by a perfluorooctylbromide emulsion. Radiother Oncol 1991; 22: 92–8
   PubMed Web of Science ®Google Scholar
• Hirst D G, Wood P J. Chlorophenoxyacetic acid derivatives as hemoglobin modifiers and tumour radiosensitizers. Int J Radiat Oncol Biol Phys 1989; 16: 1183–6
   PubMedGoogle Scholar
• Siemann D W, Alliet K L, Macler L M. Manipulations in the oxygen transport capacity of blood as a means of sensitizing tumors to radiation therapy. Int J Radiat Oncol Biol Phys 1989; 16: 1169–72
   PubMed Web of Science ®Google Scholar
• Adams G E. Radiosensitizers: a conference preview. Int J Radiat Oncol Biol Phys 1984; 10: 1181–4
   PubMedGoogle Scholar
• Coleman C N. Hypoxia in tumours: a paradigm for the approach to biochemical and physiological heterogeneity. J Natl Cancer Inst 1988; 80: 310–7
   PubMed Web of Science ®Google Scholar
• Overgaard J, Neilsen O S, Lindegaard J C. Biological basis for rational design of clinical treatment with combined hyperthermia and radiation. Physics and technology of hyperthermia, S B Field, C Franconi. Martinus Nijhoff, Amsterdam 1987; 54–79
   Google Scholar
• Overgarrd J, Nielsen O S. The role of tissue environmental factors on the kinetics and morphology of tumor cells exposed to hyperthermia. Ann NY Acad Sci 1980; 335: 254–80
   PubMedGoogle Scholar
• Jirtle R, Clifton K H, Rankin J HG. Effects of several vasoactive drugs on the vascular resistance of MT-W9B tumors in W/Fu rats. Cancer Res 1978; 38: 2385–90
   PubMed Web of Science ®Google Scholar
• Mattson J, Appelgren L, Karlsson L, Peterson H I. Influence of vasoactive drugs and ischaemia on intratumour blood flow distribution. Eur J Cancer 1978; 14: 761–4
   Google Scholar
• Knapp W H, Debatin J, Layer K, et al. Selective drug-induced reduction of blood flow in tumour transplants. Int J Radiat Oncol Biol Phys 1985; 11: 1357–66
   PubMed Web of Science ®Google Scholar
• Kallman R F, Denardo G L, Stasch M J. Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. Cancer Res 1972; 32: 483–90
   PubMed Web of Science ®Google Scholar
• Overgaard J. The future of hyperthermic oncology. Hyperthermic oncology 1992. Vol. 2. Plenary and symposia lectures, E W Gerner, T C Cetas. Arizona Board of Regents, Tuscon 1993; 87–92
   Google Scholar
• Henk J M. Does hyperbaric oxygen have a future in radiation therapy: Int J Radiat Oncol Biol Phys 1981; 7: 1125–8
   PubMedGoogle Scholar
• Rubin P, Hanley J, Keys H M, Marcial V, Brady L. Carbogen breathing during radiation therapy. The radiation therapy oncology group study. Int J Radiat Oncol Biol Phys 1979; 5: 1963–70
   PubMed Web of Science ®Google Scholar
• Zackrisson B, Franzén L, Hendriksson R, et al. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). Acta Oncol 1994; 33: 377–81
   PubMed Web of Science ®Google Scholar
• Siemann D W, Hill R P, Bush R A. The importance of the pre-irradiation breathing times of oxygen and carbogen (5% CO2; 95% O2) on the in vivo radiation response of a murine sarcoma. Int J Radiat Oncol Biol Phys 1977; 2: 903–11
   PubMed Web of Science ®Google Scholar
• Chaplin D J, Horsman M R, Siemann D W. Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate acutely and chronically hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time. Br J Cancer 1993; 68: 269–73
   PubMed Web of Science ®Google Scholar
• Horsman M R, Siemann D W, Nordsmark M, Khalil A A, Overgaard J, Chaplin D J. The combination of nicotinamide and carbogen breathing to improve tumour oxygenation prior to radiation treatment. Oxygen transport to tissue XVI, M C Hogan, O Mathieu-Costello, D C Poole, P D Wagner. Plenum Press, New York 1994; 635–42
   Google Scholar
• Brown J M. Keynote address: Hypoxic cell radiosensitizers: Where next? Int J Radiat Oncol Biol Phys 1989; 16: 987–93
   PubMedGoogle Scholar
• Brown D M, Evans J W, Brown J M. The influence of inhibitors of poly(ADP-ribose) polymerase on x-ray induced potentially lethal damage repair. Br J Cancer 1984; 49((Suppl VI))27–31
   Google Scholar
• Ben-Hur E, Utsumi H, Elkind M M. Inhibitors of poly-(ADP-ribose) synthesis enhance radiation response by differentially affecting repair of potential lethal versus sublethal damage. Br J Cancer 1984; 49((Suppl VI))39–42
   Google Scholar
• Ben-Hur E, Utsumi H, Elkind M M. Inhibitors of poly-(ADP-ribose) synthesis enhance x-ray killing of log-phase Chinese hamster cells. Radiat Res 1984; 97: 546–55
   PubMed Web of Science ®Google Scholar
• Ben-Hur E, Chen C C, Elkind M M. Inhibitors of poly-(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res 1985; 45: 2123–7
   PubMed Web of Science ®Google Scholar
• Szumiel I, Wlodek D, Johanson K J, Sundell-Bergman S. ADP-ribosylation and post-irradiation cellular recovery in two strain of L5178Y cells. Br J Cancer 1984; 49((Suppl VI))33–8
   PubMedGoogle Scholar
• Miyakoshi J, Oda W, Inagaki C. Effects of m-aminobenzamide on the response of Chinese hamster cells to hyperthermia and/or radiation. Radiat Res 1985; 102: 359–66
   PubMed Web of Science ®Google Scholar
• Raaphorst G P, Azzam E I. Poly(ADP-ribose) synthetase inhibitors increase radiation and thermal sensitivity but do not affect thermotolerance. Radiat Res 1988; 116: 442–52
   PubMed Web of Science ®Google Scholar
• Lunec J, George A M, Hedges M, Cramp W A, Whish W JD, Hunt B. Post-irradiation sensitization with the ADP-ribosyltransferase inhibitor 3-acetamidobenzamide. Br J Cancer 1984; 49((Suppl VI))19–25
   Google Scholar
• Nduka N, Skidmore C J, Shall S. The enhancement of cytotoxicity of N-Methyl-N-nitrosourea and of γ-radiation by inhibitors of poly(ADP-ribose) polymerase. Eur J Biochem 1980; 105: 525–30
   PubMedGoogle Scholar
• Chaplin D J, Trotter M J, Skov K A, Horsman M R. Modification of tumour radiation response in vivo by the benzamide analog pyrazinamide. Br J Cancer 1990; 62: 561–6
   PubMed Web of Science ®Google Scholar
• Hayaishi O, Ueda K. ADP-ribosylation reactions. Biology and medicine. Academic Press, New York 1982
   Google Scholar
• Hayaishi O, Ueda K. Poly- and mono(ADP-ribosyl)ation reactions: Their significance in molecular biology. ADP-ribosylation reactions. Biology and medicine, O Hayaishi, K Ueda. Academic Press, New York 1982; 3–16
   Google Scholar
• Shall S. ADP-ribose in DNA repair. ADP-ribosylation reactions. Biology and medicine, O Hayaishi, K Ueda. Academic Press, New York 1982; 477–520
   Google Scholar
• Shall S. Experimental manipulation of the specific activity of poly(ADP-ribose) polymerase. J Biochem 1975; 77: 2
   Google Scholar
• Purnell M R, Which W JD. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem J 1980; 185: 775–7
   PubMed Web of Science ®Google Scholar
• Preiss J, Schlaeger R, Hilz H. Specific inhibition of poly-ADP-ribose polymerase by thymidine and nicotinamide in HeLa cells. FEBS Letts 1971; 19: 244–6
   PubMed Web of Science ®Google Scholar
• Durkacz B W, Irwin J, Shall S. The effect of inhibition of (ADP-ribose)n biosynthesis on DNA repair assayed by the nucleoid technique. Eur J Biochem 1981; 121: 65–9
   PubMedGoogle Scholar
• Martin D S, Kligerman M M, Fugmann R A. Radiotherapy and adjuvant combination chemotherapy (6-aminonicotinamide and 6-mercaptopurine). Cancer Res 1958; 18: 893–6
   PubMedGoogle Scholar
• Calcutt G, Ting S M, Preece A W. Tissue NAD levels and the response to irradiation or cytotoxic drugs. Br J Cancer 1970; 24: 380–8
   PubMedGoogle Scholar
• Jonsson G G, Kjellén E, Pero R W, Cameron R. Radiosensitization effects of nicotinamide on malignant and normal mouse tissue. Cancer Res 1985; 45: 3609–14
   PubMed Web of Science ®Google Scholar
• Horsman M R, Chaplin D J, Brown J M. Radiosensitization by nicotinamide in vivo: A greater enhancement of tumour damage compared to that of normal tissues. Radiat Res 1987; 109: 479–89
   PubMed Web of Science ®Google Scholar
• Horsman M R, Hansen P V, Overgaard J. Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status. Int J Radiat Oncol Biol Phys 1989; 16: 1273–6
   PubMed Web of Science ®Google Scholar
• Horsman M R, Wood P J, Chaplin D J, Brown J M, Overgaard J. The potentiation of radiation damage by nicotin-amide in the SCCVII tumour in vivo. Radiother Oncol 1990; 18: 49–57
   PubMed Web of Science ®Google Scholar
• Lybak S, Kjellen E, Wennerberg J, Pero R. Metoclopramide enhances the effect of ionizing radiation on xenografted squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1990; 19: 1419–24
   PubMed Web of Science ®Google Scholar
• Brown J M, Lemmon M J, Horsman M R, Lee W W. Structureactivity relationships for tumour radiosensitization by analogs of nicotinamide and benzamide. Int J Radiat Biol 1991; 59: 739–48
   PubMed Web of Science ®Google Scholar
• Kjellen E, Pero R W, Nilsson P. Comparison of low dose nicotinamide versus benzamide, administered per os, as radiosensitizers in a C3H mammary carcinoma. Radiother Oncol 1988; 12: 327–31
   PubMed Web of Science ®Google Scholar
• KjellenJoiner M C, Collier J M, Johns H, Rojas A. A theraputic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated x-ray treatments. Radiother Oncol 1991; 22: 81–91
   PubMedGoogle Scholar
• Lee I, Song C W. The oxygenation of murine isografts and human tumour xenografts by nicotinamide. Radiat Res 1992; 130: 65–71
   PubMed Web of Science ®Google Scholar
• Kjellen E, Pero R W, Cameron R, Ranstam J. Radiosensitizing effects of nicotinamide on a C3H mouse mammary adenocarcinoma. A study on per os drug administration. Acta Radiol Oncol 1986; 25: 281–4
   PubMedGoogle Scholar
• Martin L M, Thomas C D, Guichard M. Nicotinamide and carbogen: relationship between pO2 and radiosensitivity in three tumour lines. Int J Radiat Biol 1994; 65: 379–86
   PubMed Web of Science ®Google Scholar
• Siemann D W, Horsman M R, Chaplin D J. The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. Radiother Oncol 1994; 31: 117–22
   PubMed Web of Science ®Google Scholar
• Lybak S, Kjellen E, Nilsson P, Tomaszewicz A, Wennerberg J, Pero R W. Normal tissue reactions in mice after combined treatment with metoclopramide and ionizing radiation. Acta Oncol 1992; 31: 469–74
   PubMed Web of Science ®Google Scholar
• Horsman M R, Høyer M, Honess D J, Dennis I F, Overgaard J. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother Oncol 1993; 27: 131–9
   PubMed Web of Science ®Google Scholar
• Chaplin D J, Horsman M R, Trotter M J. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumour. J Natl Cancer Inst 1990; 82: 672–6
   PubMedGoogle Scholar
• Wood P J, Counsell C JR, Bremner J CM, Horsman M R, Adams G E. The measurement of radiosensitizer-induced changes in mouse tumour metabolism by 31-P magnetic resonance spectroscopy. Int J Radiat Oncol Biol Phys 1991; 20: 291–4
   PubMedGoogle Scholar
• Hirst D G, Joiner B, Hirst V K. Blood flow modification by nicotinamide and metoclopramide in mouse tumours growing in different sites. Br J Cancer 1993; 67: 1–6
   PubMedGoogle Scholar
• Horsman M R, Kristjansen P EG, Mizuno M, et al. Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice. Int J Radiat Oncol Biol Phys 1992; 22: 451–4
   PubMedGoogle Scholar
• Honess D J, Bleehen N M. Effects of the radiosensitising agent nicotinamide on relative tissue perfusion and kidney function in C3H mice. Radiother Oncol 1993; 27: 140–8
   PubMedGoogle Scholar
• Kelleher D K, Vaupel P W. Nicotinamide exerts apparently opposing acute effects on microcirculatory function and tissue oxygenation in rat tumours. Int J Radiat Oncol Biol Phys 1993; 26: 95–102
   PubMed Web of Science ®Google Scholar
• Franko A J, Chapman J D, Koch C J. Binding of misonidazole to EMT6 and V79 spheroids. Int J Radiat Oncol Biol Phys 1982; 8: 737–9
   PubMedGoogle Scholar
• Hees P S, Sotak C H. Assessment of changes in murine tumour oxygenation in response to nicotinamide using 19F NMR relaxometry of a perfluorocarbon emulsion. MRM 1993; 29: 303–10
   PubMedGoogle Scholar
• Horsman M R, Nordsmark M, Khalil A A, et al. Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol 1994; 33: 371–6
   PubMed Web of Science ®Google Scholar
• Horsman M R, Nordsmark M, Khalil A, Chaplin D J, Overgaard J. Tumour radiosensitization by nicotinamide: Is it the result of an improvement in tumour oxygenation?. Oxygen transport to tissue XV, P Vaupel, R Zander, D F Bruley. Plenum Press, New York 1994; 403–9
   Google Scholar
• Hirst D G, Kennovin G D, Tozer G M, Prise V E, Flitney E W. The modification of blood flow in tumours and their supplying arteries by nicotinamide. Acta Oncol 1995; 34: 397–400
   PubMed Web of Science ®Google Scholar
• Lee I, Boucher Y, Jain R K. Nicotinamide can lower tumor interstitial fluid pressure: Mechanistic and theraputic implications. Cancer Res 1992; 52: 3237–40
   PubMed Web of Science ®Google Scholar
• Stone H B, Minchinton A I, Lemmon M, Menke D, Brown J M. Pharmacological modification of tumour blood flow: Lack of correlation between alteration of mean arterial blood pressure and changes in tumour perfusion. Int J Radiat Oncol Biol Phys 1991; 22: 79–86
   Google Scholar
• Horsman M R, Overgaard J, Christensen K L, Trotter M J, Chaplin D J. Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy. Biomed Biochim Acta 1989; 48: S251–4
   Google Scholar
• Horsman M R, Christensen K L, Overgaard J. Importance of nicotinamide dose on blood pressure changes in mice and humans. Int J Radiat Oncol Biol Phys 1994; 29: 455–8
   PubMedGoogle Scholar
• Huang T F, Chao C C. The effect of niacinamide on cerebral circulation. Proc Soc Exp Biol Med 1960; 105: 551–3
   PubMed Web of Science ®Google Scholar
• Schlappack O K, Delic J I, Bush C, Stanley J A, Steel G G. The response of murine stem spermatogonia to radiation combined with 3-aminobenzamide. Int J Radiat Biol 1987; 52: 7–19
   Google Scholar
• Haustermans K, van der Kogel A J, Vanacker B, van der Schueren E. Influence of combined use of nicotinamide and carbogen on rat spinal cord radiation tolerance. Radiother Oncol 1994; 31: 123–8
   PubMedGoogle Scholar
• Rojas A, Kjellen E, Joiner M C. Does nicotinamide inhibit repair of radiation damage in vivo? (abstract). Br J Radiol 1990; 63: 914
   Google Scholar
• Hendry J H, Sutton M L. Care with radiosensitizers. Br J Radiol 1978; 51: 927–8
   PubMed Web of Science ®Google Scholar
• Hendry J H. Quantitation of the radiotheraputic importance of naturally-hypoxic normal tissues from collated experiments with rodents using single doses. Int J Radiat Oncol Biol Phys 1979; 5: 971–6
   PubMed Web of Science ®Google Scholar
• Hendry J H. Radionecrosis of normal tissue: Studies on mouse tails. Int J Radiat Biol 1978; 33: 47–55
   Web of Science ®Google Scholar
• Hendry J H, Moore J V, Hodgson B W, Keene J P. The constant low oxygen concentration in all the target cells for mouse tail radionecrosis. Radiat Res 1982; 92: 172–81
   PubMed Web of Science ®Google Scholar
• Horsman M R, Chaplin D J, Overgaard J. Enhancement by nicotinamide of the in vivo interaction between radiation and hyperthermia (abstract). Int J Radiat Biol 1989; 55: 886
   Google Scholar
• Chaplin D J, Horsman M R, Aoki D S. Nicotinamide, fluosol DA and carbogen: A strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br J Cancer 1991; 63: 109–13
   PubMed Web of Science ®Google Scholar
• Kim J H, Alfieri A A, Kim S H. Radiosensitization of a hypoxic murine mammary adenocarcinoma by mild hyperthermia (41°C) or nicotinamide and by concomitant modalities. Abstracts of the Thirty-Sixth Annual Meeting of the Radiation Research Society, Philadelphia, PA, April 16–21, 1988, Eh-3
   Google Scholar
• Kjellen E, Pero R W, Nilsson P, Hill S. Effect of hyperthermia and/or nicotinamide on the radiation response of a C3H mammary carcinoma. Eur J Cancer Clin Oncol 1989; 25: 1733–7
   PubMedGoogle Scholar
• Lee I, Kim J H, Levitt S H, Song C W. Increases in tumour response by penloxifylline alone or in combination with nicotinamide. Int J Radiat Oncol Biol Phys 1992; 22: 425–9
   PubMed Web of Science ®Google Scholar
• Lee I, Levitt S H, Song C W. Improved tumour oxygenation and radiosensitization by combination with nicotinamide and pentoxifylline. Int J Radiat Biol 1993; 64: 237–44
   PubMed Web of Science ®Google Scholar
• Rojas A, Hodgkiss R J, Stratford M RL, Dennis M F, Johns H. Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitization with carbogen and nicotinamide: Clinical considerations. Br J Cancer 1993; 68: 1115–21
   PubMed Web of Science ®Google Scholar
• Greegard P. Water-soluble vitamins. The vitamin B complex. The pharmacological basis of therapeutics, 5th ed, L S Goodman, A Gillman. Macmillan, New York 1975; 1549–63
   Google Scholar
• Eder H A. Drugs used in prevention and treatment of atherosclerosis. The pharmacological basis of theraputics, 5th ed, L S Goodman, A Gillman. Macmillan, New York 1975; 744–52
   Google Scholar
• Hawkins D R. Treatment of schizophrenia based on the medical model. J Schizophrenia 1968; 2: 3–10
   Google Scholar
• Ramsey R A, Ban T A, Lehmann H E, Saxena M A, Bennett J. Nicotinic acid as adjuvant therapy in newly admitted schizophrenia patients. Can Med Ass J 1970; 102: 939–42
   PubMedGoogle Scholar
• Hofer A. Safety, side effects and relative lack of toxicity of nicotinic acid and nicotinamide. Schizophrenia 1969; 1: 78–87
   Google Scholar
• Mosher L R. Nicotinic acid side effects and toxicity: A review. Am J Psychiat 1970; 126: 1290–6
   PubMed Web of Science ®Google Scholar
• Herter F P, Weissman S G, Thompson H G, Jr, Hyman G, Martin D S. Clinical experience with 6-aminonicotinamide. Cancer Res 1961; 21: 31–7
   PubMed Web of Science ®Google Scholar
• Perlia C P, Kofman S, Sky-Peck H, Taylor S G, III. Clinical use of 6-aminonicotinamide in patients with disseminated neoplastic disease. Cancer 1961; 14: 644–8
   PubMedGoogle Scholar
• Shapiro D M, Dietrich L S, Shils M E. Quantitative biochemical differences between tumour and host as a basis for cancer chemotherapy. V. Niacin and 6-aminonicotinamide. Cancer Res 1957; 17: 600–4
   PubMedGoogle Scholar
• Weinstein L. Antimicrobial agents: Drugs used in the chemotherapy of tuberculosis and leprosy. The pharmacological basis of theraputics, 5th ed, L S Goodman, A Gillman. Macmillan, New York 1975; 1201–23
   Google Scholar
• Weinstein L. Antimicrobial agents: General considerations. The pharmacological basis of theraputics, 5th ed, L S Goodman, A Gillman. Macmillan, New York 1975; 1090–1112
   Google Scholar
• McDermott W, Ormond L, Muschenheim C, Deuschle K, McCune R M, Tompsett R. Pyrazinamide-isoniazid in tuberculosis. Am Rev Tuberc Pulm Dis 1954; 69: 319–33
   PubMedGoogle Scholar
• Zackheim R G. Topical 6-aminonicotinamide plus oral nicotinamide therapy for psoriasis. Arch Dermatol 1978; 114: 1632–8
   PubMed Web of Science ®Google Scholar
• Green R G. Subclinical pellagra: its diagnosis and treatment. Schizophrenia 1970; 2: 70–9
   Google Scholar
• Chouinard G, Young S N, Annable L, Sourkes T L. Tryptophan-nicotinamide combination in depression. Lancet 1977; 1: 249
   PubMedGoogle Scholar
• Greenbaum G HC. An evaluation of niacinamide in the treatment of shildhood schizophrenia. Am J Psychiat 1970; 127: 89–92
   PubMedGoogle Scholar
• Winter S L, Boyer J L. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). N Engl J Med 1973; 289: 1180–2
   PubMed Web of Science ®Google Scholar
• Vague P, Vialettes B, Lassmann-Vague V, Vallo J J. Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet 1987; 1: 619–20
   PubMedGoogle Scholar
• Chase H P, Butler-Simon N, Garg S, McDuffie M, Hoops S L, O'Brien D. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin dependent) diabetes mellitus. Diabetologia 1990; 33: 444–6
   PubMed Web of Science ®Google Scholar
• Elliott R B, Chase H P. Prevention or delay of type 1 (insulin dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991; 35: 362–5
   Google Scholar
• Neumann R, Rappold E, Pohl-Markl H. Treatment of polymorphous light eruption with nicotinamide: A pilot study. Br J Dermat 1986; 115: 77–80
   PubMed Web of Science ®Google Scholar
• Haslam R H, Dalby J T, Rademaker A W. Effects of megavitamin therapy on children with attention deficit disorders. Pediatrics 1984; 74: 103–11
   PubMed Web of Science ®Google Scholar
• Zackheim H S, Vasily D B, Westphal M L, Hastings C W. Reactions to niacinamide. J Am Acad Dermatol 1981; 4: 736–7
   PubMed Web of Science ®Google Scholar
• DeVries J X, Gunthert W, Ding R. Determination of nicotinamide in human plasma and urine by ion-pair reversed phase high performance liquid chromotography. J Chromatogr 1980; 221: 161–5
   PubMedGoogle Scholar
• Stratford M RL, Rojas A, Hall D W, et al. Pharmacokinetics of nicotinamide and its effects on blood pressure, pulse and body temperature in normal human volunteers. Radiother Oncol 1992; 25: 37–42
   PubMed Web of Science ®Google Scholar
• Horsman M R. Blood flow modification and oxygenation of experimental tumours. Bioreductive drugs, sensitizers, oxygen and radiotherapy, W Dobrowsky. Springer-Verlag, Vienna 1993; 85–100
   Google Scholar
• Denekamp J. ARCON: accelerated radiotherapy with carbogen and nicotinamide. Eur Cancer News 1991; 4: 3–5
   Google Scholar
• Hoskin P J, Saunders M I. ARCON. Clin Oncol 1994; 6: 281–2
   Google Scholar
• Brown J M. Carbogen and nicotinamide: Expectations too high? Radiother Oncol 1992; 24: 75–6
   PubMedGoogle Scholar
• Horsman M R. Carbogen and nicotinamide: Expectation to high? Radiother Oncol 1992; 24: 121–2
   PubMedGoogle Scholar
• Khalil A A, Horsman M R, Overgaard J. The importance of determining necrotic fraction when studying the effect of tumour volume on tissue oxygenation. Acta Oncol 1995; 34: 297–300
   PubMed Web of Science ®Google Scholar